



# VASCULAR COGNITIVE IMPAIRMENT:

## Sweating the Small Stuff

Eric E. Smith, MD, MPH  
Associate Professor of Neurology  
Dept of Clinical Neurosciences  
Hotchkiss Brain Institute  
University of Calgary

October 30, 2012

---

---

---

---

---

---

---

---

### Disclosures

Grateful acknowledgment of funding from:

Alberta Innovates – Health Solutions, Canadian Stroke Network, Heart and Stroke Foundation Canada, CIHR, National Institutes of Health, Alzheimer Society of Canada, Hotchkiss Brain Institute.

---

---

---

---

---

---

---

---

### Outline

- Background: dementia and the pathologies that cause dementia.
- Cerebral small vessel disease and dementia.
- Ongoing projects in our clinical research “lab”.

---

---

---

---

---

---

---

---

Lifetime risk of dementia in women is 1 in 4 and in men is 1 in 6.

Alzheimer's disease (AD) is 7<sup>th</sup> leading cause of death in Canada.

(Lifetime risk of: breast cancer 1 in 8, prostate cancer 1 in 6, Parkinson's 1 in 15, epilepsy 1 in 26, multiple sclerosis 1 in 500.)

Seshadri, et al. Lancet Neurol 2007;6:1106-1114.  
Statistics Canada (2008).

---

---

---

---


---

---

---

---

### Neuropathologies of Dementia



- Alzheimer's + CVD
- Pure Alzheimer's
- Pure Vascular Dementia
- Lewy Bodies
- Unclear

Schneider et al, Neurology 2007;69:2197-2204.

---

---

---

---

---

---

---

---

### Pathologies of Dementia

Neuritic Plaques



7%

Neurofibrillary Tangles



28%

Small Vessel Disease



17%

Cerebral Amyloid Angiopathy



11%

Atrophy

20%

Lewy Bodies



4%

Matthews, et al. PLoS Med 2009;6:e1000180

---

---

---

---

---

---

---

---



---

---

---

---

---

---

---

---

### Cerebral Small Vessel Disease (The Small Stuff)

- Pathology: Arteriolosclerosis or Cerebral amyloid angiopathy.
- Consequences: Loss of vascular integrity (bleeding), ischemia (infarction), altered vascular reactivity (disturbed blood flow regulation?).

---

---

---

---


---

---

---

---

### Arteriolosclerosis



Smith, E. E. and R. N. Auer (2010). Hypertensive Arteriopathy. Microbleeds: From Pathophysiology to Clinical Practice. D. Werning, Cambridge, Cambridge University Press.

---

---

---

---


---

---

---

---

## Cerebral Amyloid Angiopathy



- Accumulation of beta-amyloid in the media and adventitia of small arteries in the cortex and leptomeninges.
- Loss of vascular integrity.
- Cause of lobar intracerebral hemorrhage in older persons
- Associated with cognitive impairment.

Chen Y-W, Lee M-J, Smith EE. Cerebral amyloid angiopathy in East and West. International Journal of Stroke. 2010.

---

---

---

---

---

---

---

---

---

---

---

---

## Three Major Questions

1. Can we diagnose the pathologies that cause dementia in living people?
2. Does preventing amyloid build up prevent AD?
3. Does treating vascular risk factors prevent dementia?

---

---

---

---

---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

---

---

---

---

## Overview of My Research

Overall objective: to improve our understanding of cerebral small vessel disease by:

- a) Measuring the prevalence and impact of small vessel diseases in the community throughout the lifespan (PURE-MIND study)
- b) Improving diagnosis of small vessel diseases in persons with cognitive symptoms at risk for dementia (BRAIN-IMPACT study)
- c) Understanding the mechanisms by which small vessel diseases impact brain blood flow, structure and function (FAVR study).

---

---

---

---


---

---

---

---

## Covert Brain Infarcts



---

---

---

---


---

---

---

---

## White Matter Lesions



---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

**Study Objectives**

- What is known: covert infarcts and white matter lesions of presumed vascular origin are seen in elderly preceding dementia.
- Objectives of PURE-MIND:
  - Prevalence of cerebral small vessel disease in 40-70 yrs.
  - Earliest changes in cognition and brain structure caused by vascular risk and covert small vessel disease.

---

---

---

---

---

---

---

---

## PURE-MIND Study Design

- Longitudinal cohort study.
- Population-based recruitment in communities centred around Vancouver, Hamilton, Ottawa and Quebec.
- Substudy of the Prospective Urban Rural Epidemiological Study (PURE).
- Participants are 40-70 without stroke or dementia.
- Measurements: brain MRI, MoCA, Digit Symbol Substitution test, gait speed and instrumental activities of living (SAGE).
- Pilot phase (n=800) completed funded by CSN, HSFC and CIHR.

---

---

---

---


---

---

---

---

## BRAIN ATROPHY



Segmented brain produced by FreeSurfer.  
Red line indicates pial surface, yellow line white matter/gray matter surface.

---

---

---

---


---

---

---

---

## CORTICAL THICKNESS



---

---

---

---

---

---

---


---

## Prevalence of Small Vessel Disease by Age

Age	N	Infarcts (%)	Microbleeds (%)	Extensive white matter lesions <sup>1</sup> (%)	Any of either infarcts, microbleeds or white matter lesions (%)
40-49	250	3.2	2.0	1.3	6.4
50-59	307	9.8	4.9	7.1	18.8
60-70	243	12.8	9.1	23.3	34.9

Smith EE et al. Rationale, design and preliminary findings of the Prospective Urban-Rural Epidemiologic Mind (PURE-MIND) MRI study, 2011: oral presentation at the Canadian Stroke Congress (abstract).

## Prevalence of Covert Brain Infarcts by Age



From Vermeer SE, Longstreth WT, Jr., Koudstaal PJ. Silent brain infarcts: a systematic review. *Lancet Neurol*. 2007;6:611-619

## Impairments Associated with Covert Infarcts

Characteristic	Covert Infarct (n=69)	No Covert Infarct (n=731)	P value
Age (years)	59.1 ± 7.6	54.1 ± 7.9	<0.001
Male sex	48%	41%	0.31
MoCA total score*	26 [25, 28]	27 [25, 28]	0.03
MoCA ≥26	59%	69%	0.10
Normal MoCA visuospatial/executive subscore <sup>†</sup>	42%	57%	0.02
Digit Symbol Substitution Test*	63.0 ± 16.8	70.1 ± 15.8	<0.001
CES-D <sup>††</sup>	4 [1, 10.5]	4 [2, 9]	0.69
CES-D ≥16	12%	10%	0.68
Timed gait (sec) <sup>‡</sup>	8.3 ± 4.1	7.3 ± 2.0	<0.001
Mild cognitive impairment	14%	9%	0.14



### Risk Factors for Covert Infarcts

Characteristic	Covert Infarct (n=69)	No Covert Infarct (n=731)	P value
Age (years)	59.1 ± 7.6	54.1 ± 7.9	<0.001
Male sex	48%	41%	0.31
Diabetes mellitus	10%	6%	0.18
Cigarette smoker			
Current	14%	7%	0.02
Former	45%	39%	
Never	41%	54%	
Systolic BP	138 ± 16 mmHg	128 ± 16 mmHg	<0.001
Diastolic BP	83 ± 10	79 ± 10	0.002
Waist:hip ratio	0.90±0.09	0.87±0.10	0.02
Body mass index	28.7 ± 5.9	26.8 ± 5.2	0.003

---

---

---

---

---

---

---

---

---

---

### Small Vessel Disease and MCI

- Cerebral small vessel disease is a surprisingly strong contributor to the risk of dementia.
- However, there has been little research on how small vessel disease contributes to conversion from MCI to AD.
- How does AD interact with small vessel disease to cause cognitive decline in MCI?

---

---

---

---

---

---

---

---

---

---

### Brain Imaging and NeuroPsychological Assessment of Cognitive Impairment (Brain-IMPACT)

- Design: Observational prospective cohort study.
- Outcome: Neuropsychological test performance.
- 66 patients in Calgary, 100 in Boston.
- Study procedures: MRI, neuropsychological testing, PIB-PET (Boston cohort only).
- Funding: U.S. NIH, Alberta Heritage Fund for Medical Research.
- Study completion anticipated in March 2013.

---

---

---

---

---


---

---

---

---

---



**Hypotheses:**

- Small vessel disease and AD are competing risks for developing MCI.
- MCI patients with SVD will have greater impairment in processing speed and executive function.
- Small vessel disease and AD will independently predict decline, but the rate of decline will be faster in AD.

---

---

---

---


---

---

---

---

### Blood Flow Regulation in Cerebral Amyloid Angiopathy (CAA)



**Objectives:**

1. To determine whether blood flow regulation is disturbed in cerebral amyloid angiopathy compared to Alzheimer's disease and arteriosclerotic disease.
2. To identify the cognitive profile of CAA compared to AD, mild stroke, and healthy controls.

---

---

---

---


---

---

---

---

### fMRI Activation



18 CAA (diagnosed by Boston criteria) compared to 18 age and sex-matched controls

---

---

---

---

---


---

---


---

## Vascular-Neuronal Decoupling in CAA

Visual fMRI BOLD amplitude



Visual Evoked Potential Amplitude



Means  
Control: 3.57  
CAA: 2.57

## Summary

- Cerebral small vessel disease is common and is a surprisingly strong contributor to late-life dementia, although not usually the sole cause of dementia.
- We use neuroimaging to study the prevalence and consequences of cerebral small vessel disease in the general population and in high-risk groups, and in selected patients with cerebral small vessel disease to understand mechanisms of the disease.

## Acknowledgements

### PURE-MIND Study

#### PHRI

Salim Yusuf  
Marrin O'Donnell  
Koon Teo  
Sumathy Rangarajan  
Jane DeJesus  
Bob Hart  
Jim Sahlas

#### Univ Calgary

Eric Smith  
Cheryl McCreary  
Anna Charlton  
Richard Frayne  
Jyesh Modi  
Mayank Goyal  
Peter Dickhoff

#### Ontario Centre for Stroke Recovery

Sandra Black  
Stephen Strother

#### Connectin Stroke Work Group

#### Quebec

Gilles Dagenais

#### Vancouver

Scott Lator

#### Ottawa

Andreas Wielgosz  
Grant Sionts  
Mike Sharma

### Brain-IMPACT Study

#### Univ Calgary

Cheryl McCreary  
Anna Charlton  
Emily Donaldson  
Richard Frayne  
Mayank Goyal  
Mass General Hospital  
Deborah Blacker  
Keith Johnson  
Bruce Fischl  
David Siler

### FAVR Study

#### Univ Calgary

Marc Poulin  
Brad Goodyear  
Richard Frayne  
Cheryl McCreary  
Anna Charlton  
Emily Donaldson  
Jennifer Chan  
Andrew Beaudin  
Karla Garcia-Sanchez  
Stefano Pica

[www.ucalgary.ca/esmithresearch](http://www.ucalgary.ca/esmithresearch)

